GLOBAL PHARMACEUTICAL CHEMICALS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In February 2023, Piramal Pharma Solutions, a patient-centric Contract Development and Manufacturing Organization (CDMO) and subsidiary of Piramal Pharma Ltd, a pharmaceutical company. stated that it has commenced producing initial batches of active pharmaceutical ingredients (APIs) in new reactor suites at its site in Michigan, U.S.
• In January 2023, Agilent Technologies Inc., a leader in the life sciences, diagnostics, and applied chemical markets, stated that it will invest approximately USD 725 million to expand therapeutic nucleic acid manufacturing capacity in response to the rapidly growing USD 1 billion industry and strong demand for the company's high-quality active pharmaceutical ingredients (API)
• In August 2022, WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced the ground-breaking of its new 190-acre pharmaceutical manufacturing facility in Middletown, U.S. This site, announced in June 2021, will be WuXi STA's second plant in the U.S., providing increased capacity and greater flexibility to satisfy the demands of customers in the U.S. and around the world.
• In March 2021, Avista Capital Partners, a leading private equity firm focused solely on healthcare, announced that it has signed a definitive agreement to invest in eMolecules, a novel and rapidly growing e-procurement platform for high-value chemicals and bioreagents used by leading pharmaceutical companies in drug discovery.